Risk factors
Allogene Therapeutics (ALLO) risk factors
Item 1A of every Allogene Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors88 risks12 new6 dropped25 reworded
Allogene faces capital constraints with cash down to $258.3 million, forcing manufacturing cutbacks and trial adjustments following a Grade 5 serious adverse event in the ALPHA3 trial.
Filed Mar 12, 2026 - FY2024 10-K risk factors82 risks
Company is a clinical-stage biopharmaceutical firm reliant on novel allogeneic T cell therapies and gene editing technologies. It faces substantial financing needs, manufacturing hurdles, and reliance on key partners like Cellectis and Foresight Diagnostics.
Filed Mar 13, 2025